Clinical trials: Mental
Alzheimer's Disease
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.
- Trial name
- NCT00939783
- Testing
- Dimebon
- Where
- 105 sites in United States, Canada and 1 more
- Volunteers
- 649 people
- Sponsor
- Pfizer
Opioid-Induced Constipation
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901341
- Testing
- CB-5945
- Volunteers
- 44 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Erectile Dysfunction
Long-term Safety of TPN171H Tablet in Erectile Dysfunction.
This is a multicenter, open study to evaluate the long-term safety and efficacy of TPN171H in men with erectile dysfunction.
- Trial name
- NCT06301854
- Testing
- TPN171H
- Where
- 34 sites in China
- Volunteers
- 472 people
- Sponsor
- Vigonvita Life Sciences
Schizophrenia
Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.
- Trial name
- NCT00805454
- Testing
- OPC-34712
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alcohol Use Disorder
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including…
- Trial name
- NCT06817356
- Testing
- Mazdutide
- Where
- 25 sites in United States
- Volunteers
- 308 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in…
- Trial name
- COMPASS (NCT00629551)
- Testing
- saredutant (SR48968), paroxetine
- Where
- 8 sites in United States, Chile and 6 more
- Volunteers
- 825 people
- Sponsor
- Sanofi
Schizophrenia
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
The purpose of this study is to evaluate the effect of AMG 747 on negative symptoms of schizophrenia in patients who are stable on current antipsychotic treatment.
- Trial name
- NCT01568229
- Testing
- AMG 747
- Where
- 44 sites in United States, Czechia and 4 more
- Volunteers
- 111 people
- Sponsor
- Amgen
PTSD
Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD
The goal of this long-term follow-up study is to measure how long effects of MDMA-assisted therapy last in participants with PTSD who were treated in a prior Phase 3 clinical trial of MDMA-assisted therapy.
- Trial name
- MPLONG (NCT05066282)
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 186 people
- Sponsor
- Resilient Pharmaceuticals
Restless Legs Syndrome
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
This double-blind study will evaluate the pharmacokinetics of a single dose of morphine or gabapentin derived from gabapentin enacarbil (GEn) after administration of morphine and GEn alone and in combination as well as the…
- Trial name
- NCT01476124
- Testing
- GEn 600 mg, Morphine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Obsessive Compulsive Disorder
Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
To evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) with a diagnosis of anxiety…
- Trial name
- SPRITES (NCT01302080)
- Testing
- sertraline, psychotherapy
- Where
- 44 sites in United States
- Volunteers
- 941 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Potential Treatment for Alcohol Dependence-Alcohol Interaction
Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)
The purpose of this clinical study is to assess pharmacokinetic interactions between ethanol (EtOH) and PT150 (900 mg qd) in non-treatment-seeking alcohol-experienced volunteers-(to include military service members, veterans…
- Trial name
- NCT04331288
- Testing
- PT150, Beverage
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pop Test Oncology LLC
Cognitive Disorders
Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702
GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men and women of no child beading potential to investigate repeated…
- Trial name
- NCT00950586
- Testing
- GSK1043702, Dextromethorphan
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
General Anxiety Disorder
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety in Adolescents
Trial title: A Randomized, Double-blind Sham-controlled Clinical Trial to Evaluate The Efficacy of Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety in Adolescents - The Modius…
- Trial name
- NCT06956105
- Testing
- Modius Calm
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Neurovalens Ltd.
Major Depressive Disorder
Aripiprazole for the Augmentation of Antidepressant Therapy
The study aims to evaluate effectiveness and tolerability of aripiprazole augmentation in outpatients with major depressive disorder who have had inadequate response to antidepressants in Taiwan clinical practice.
- Trial name
- NCT01429831
- Testing
- Aripiprazole
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Tourette's Syndrome
A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome
The purpose of this clinical trial is to study the therapeutic effect of tetrabenazine MR in children with Tourette's Syndrome, as measured by the improvement in total tic score of the Yale Global Tic Severity Scale (YGTSS).
- Trial name
- TBZ-MR (NCT01133353)
- Testing
- Tetrabenazine MR
- Sponsor
- Bausch Health Americas, Inc.
Primary Insomnia
Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability
To assess next day driving ability and psychomotor/memory function following a single night time dose of eszopiclone in insomnia patients.
- Trial name
- NCT00368056
- Testing
- Eszopiclone
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms
- Trial name
- NCT00645229
- Testing
- Ziprasidone
- Where
- Portugal
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Treatment-Resistant
An Epidemiology Study of Treatment Resistant Depression in the United States (US)
The purpose of this study is to describe the epidemiology of Treatment Resistant Depression (TRD) in the US, including the population incidence of TRD, and TRD as a proportion of Pharmacologically Treated Depression (PTD), and…
- Trial name
- NCT03109002
- Volunteers
- 200,000 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
This is a Phase 1/1b, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL921 in healthy…
- Trial name
- NCT07758595
- Testing
- DNL921
- Where
- United Kingdom
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.